
|Articles|October 1, 2001
- Pharmaceutical Executive-10-01-2001
- Volume 0
- Issue 0
National Crisis Supercedes Coverage Debate
Efforts to craft a Medicare pharmacy benefit may be sidelined by repercussions from the September attack.
Advertisement
Articles in this issue
over 24 years ago
National Crisis Supercedes Coverage Debateover 24 years ago
PBMs: Merck-Medco in the Hot Seatover 24 years ago
A Five-Year Forecast: Clear Seas Ahead?over 24 years ago
Weak Bones, Strong Marketover 24 years ago
Approvals: Novartis’ Silver Liningover 24 years ago
Pfizer and others Pitch Inover 24 years ago
Oncology: EMEA Approval Lagsover 24 years ago
Illegal Sales in Indiaover 24 years ago
Health Plan Premiums: Pharma Takes the Blameover 24 years ago
Little Elan Becomes a Big DealAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Economics of the 340B Drug Pricing Program: Strategic Imperatives for the Life Sciences Industry in 2026
2
Eli Lilly and Abbisko Announce Drug Development Collaboration
3
FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer
4
Pharmaceutical Executive Daily: Eli Lilly and Abbisko Announce Drug Development Collaboration
5




